Recently several different JAK2 exon12 mutations have been identified in V617F negative polycythaemia vera (PV) or idiopathic erythrocytosis (IE) patients. The patients present with erythrocytosis, ligand-independent cell growth and low serum erythropoietin (EPO) levels. Within this group, a deletion of amino acids 542-543 (N542-E543del) of JAK2 is most prevalent. We have previously shown that in the presence of JAK2 V617F , suppressor of cytokine signalling 3 (SOCS3) is unable to negatively regulate EPO signalling and proliferation of V617F-expressing cells. Here we report a PV patient heterozygous for the somatic JAK2 N542-E543del mutation and a previously unreported germline mutation within the SH2 domain of SOCS3 (F136L). Interestingly, the SOCS3 F136L mutation was detected in a Japanese myeloproliferative disorder patient cohort at double the frequency of healthy controls. Cells expressing SOCS3 F136L had markedly elevated EPO-induced proliferation and extended EPO-induced JAK2 phosphorylation. Additionally, compared to wild-type SOCS3, mutant SOCS3 had an extended half-life in the presence of JAK2 and JAK2 N542-E543del . Our findings suggest that this loss-of-function SOCS3 mutation may have contributed to disease onset by causing deregulated JAK2 signalling in the presence of a constitutively active JAK2 N542-E543del mutant.
signalling is tightly regulated by phosphatases, such as SHP1, SHP2, and members of the suppressors of cytokine signalling family (SOCS), particularly SOCS3 (Richmond et al, 2005) . Constitutive activation of the pathway is associated with erythrocytosis and the myeloproliferative disorder (MPD) polycythaemia vera (PV).
The recently identified somatic gain-of-function JAK2 V617F mutation has been associated with over 90% of PV cases, but also with essential thrombocythaemia (ET) and idiopathic myelofibrosis (IMF). Mutation of valine to phenylalanine at amino acid 617 is thought to interfere with an autoinhibitory interaction between the JH2 domain and the catalytic groove of JH1 within JAK2 thereby rendering the kinase constitutively active (Saharinen et al, 2003; Kralovics et al, 2005) . While the V617F mutation is located on exon 14 of JAK2, recently a number of other mutations have been identified on exon 12. Patients bearing an exon 12 mutation present with a phenotype characterised by distinct erythrocytosis, ligandindependent cell growth and low serum EPO levels (Scott et al, 2007) . Within the group of exon 12 mutations deletions of amino acids 542-543 (N542-E543del) have been observed most frequently. To date, the molecular mechanism of how the deletion of these two amino acids contributes to disease onset has not been elucidated (Pietra et al, 2008) . SOCS proteins are important negative regulators of JAKs and cytokine receptors and SOCS3 is known to regulate signalling of various cytokines including EPO. SOCS1 and SOCS3 inhibit catalytic activity of JAK2 by binding to the JH1 kinase domain via their kinase inhibitory region (KIR) (Nicholson et al, 1999) . Additionally, SOCS3 can bind via its SH2 domain to the cytoplasmic domain of the EPOR. SOCS3 can bind tyrosine 401 thereby competing with STAT5 and SHP-2, and also tyrosines 429/431 where SHP-1 also interacts with the EPOR (Sasaki et al, 1999 (Sasaki et al, , 2000 . The ability to interact with both, JAK and a cognate receptor has proven to enhance the inhibitory activity of SOCS3 (Cohney et al, 1999; Nicholson et al, 2000) .
We have previously shown that in the presence of JAK2 V617F , SOCS3 was no longer able to regulate the EPO signalling pathway and proliferation of cells expressing both JAK2 V617F and EPOR (Hookham et al, 2007) . We further observed SOCS3 tyrosine phosphorylation in the presence of JAK2 V617F or exon 12 mutants and identified stabilised and tyrosine phosphorylated SOCS3 as a potential biomarker for MPDs (Elliott et al, 2009 ).
The PV patient reported here was heterozygous for the acquired somatic JAK2 N542-E543del exon 12 mutation and a previously unreported germline SOCS3 F136L mutation. We have found the SOCS3 F136L mutation in a Japanese MPD patient cohort and investigated the functional significance of this mutation. We show here that the SOCS3 F136L mutation prolonged both SOCS3 half-life and EPO-dependent JAK2 phosphorylation. Moreover this SOCS3 mutant did not regulate EPO-induced cell proliferation, and in combination with the exon 12 mutation, SOCS3 F136L potentially contributed to disease pathogenesis by deregulating wild-type JAK2 and mutant JAK2 signalling.
Materials and methods

Sequencing of SOCS3
SOCS3 was amplified by polymerase chain reaction using specific primers (forward 5′-GTCCTGGTGGGACGATAGCA-3′; reverse 5′-CCCTGGCAGTTCTCATTAGTTCA-3′). Purified amplification products were sequenced with the Applied Biosystems 3130 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA) in both directions using the BigDye Terminator v3.1 Cycle Sequencing Kit (Bromborough, Wirral, UK) (forward primer 5′-CGCTCGCGCCTTCCTCTCC-3′; reverse primer 5′-CCCGGAGTAGATGTAATAGGC-3′).
Cells and transfections
Ba/F3 cells were retrovirally infected with EPOR pMX-IRES-CD2 and JAK2 V617F pMX-IRES-GFP, JAK2 pMX-IRES-GFP, JAK2N542-E543del pMX-IRES-GFP, SOCS3 pMX-IRES-CD4, SOCS3F136L pMX-IRES-CD4 as previously described (Dusa et al, 2008) . Cell lines were grown in RPMI 1640 medium (PAA Laboratories, Pasching, Austria) supplemented with 10% foetal calf serum (FCS) (PAA), 100 μ/ml penicillin (PAA), 100 μg/ ml streptomycin (PAA), 2 mmol/l L-glutamine (PAA) and 1 μ/ml EPO (kind gift from Professor Terry Lapin).
293T cells were cultured in Dulbecco's modified Eagle medium (PAA) with 10% FCS, 100 μ/ml penicillin, 100 lg/ml streptomycin and 2 mmol/l L-glutamine. The cells were transiently transfected with EPOR pMX-IRES-CD2, JAK2 pRK, JAK2V617F pRK, JAK2N542-E543del pRK, SOCS3 pME18S Flag and SOCS3F136L pME18S Flag as appropriate using calcium phosphate precipitation reagents by standard protocols (Sigma Aldrich, Poole, Dorset, UK).
Immunoprecipitation and immunoblotting
293T cells were stimulated with 50 μ/ml EPO for 20 min and treated with 60 μg/ml cycloheximide (Sigma Aldrich) when appropriate for times indicated. The cells were lysed in Triton X-100 lysis buffer (10 mmol/l Tris pH 7·4, 150 mmol/l NaCl, 1 mmol/l EDTA pH 8·0, 1% Triton X-100, 0·1% sodium dodecyl sulphate (SDS), 1 μmol/l Na 3 VO 4 , 1 mmol/l phenylmethylsulphonyl fluoride, 10 μg/ml leupeptin, and 10 μg/ml aprotinin). Lysates were immunoprecipitated with anti-JAK2 (Upstate Biotechnology, Lake Placid, NY, USA) or anti-SOCS3 (C204, IBL, Takasaki-Shi, Gunma, Japan) as required, resolved on SDSpolyacrylamide gels and transferred onto Immobilon membranes (Millipore, Billerica, MA, USA). Western blots were probed with anti-phosphotyrosine clone 4G10 (Upstate Biotechnology), anti-JAK2 (Upstate Biotechnology), anti-M2 (Sigma Aldrich), anti-M20 (Santa Cruz Biotechnology, Heidelberg, Germany) or anti-SOCS3 clone 008 (Fusion Antibodies, Belfast, UK).
Densitometry analysis
Densitometry was performed using Adobe Photoshop CS4. The intensity of a phosphotyrosine band is expressed as relative intensity. The data was calculated as a ratio of absolute intensities of each phosphotyrosine band and a correlating protein band. Statistical analysis could not be performed on the results because only one intensity value was obtained per band.
Proliferation assay
Ba/F3 cell lines were seeded at 3 × 10 4 /ml and grown in RPMI 1640 medium as described above in the presence of absence of 0·5, 1 or 5 μ/ml EPO as indicated. Viable cell numbers were assessed every 0, 24 and 48 h by Trypan Blue exclusion assay and 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay as described (Tannahill et al, 2005) . Statistical analysis was carried out using Student t test.
Results
SOCS3 F136L is unable to regulate cytokine signalling and cell proliferation
This previously unreported SOCS3 F136L mutation was discovered in a PV patient who was additionally heterozygous for the JAK2 N542-E543del mutation. The 30-year-old female presented with persistently elevated haemoglobin associated with erythrocytosis. Bone marrow analysis revealed a markedly hypercellular marrow with a mild increase in reticulin, features consistent with PV. When testing other members of the patient's family we detected that the patient's mother was also heterozygous for the SOCS3 F136L mutation but did not present with an additional JAK2 mutation. Therefore it seems that alone the SOCS3 mutant does not cause an abnormal phenotype although a mild abnormality caused by the mutation could be controlled by the still present wild-type SOCS3 and could therefore escape detection. Another option could be that a possible phenotypic change induced by the SOCS3 F136L mutant could be dependent on the mutational burden of the patient as has also been suggested for the JAK2 V617F mutant (Tiedt et al, 2008) .
The mutation involves a C to A base change at position 408 which leads to a substitution of phenylalanine to leucine at amino acid 136 (SOCS3 F136L ) ( Fig 1A) . Phenylalanine 136 is located in the SOCS3 SH2 domain, a region which is essential for interaction with JAK2 and the EPOR and disruption of the SH2 domain abrogates the regulatory function of SOCS3 (Sasaki et al, 2000) .
Interestingly, we also detected this mutation in a Japanese MPD patient cohort at double the frequency of healthy control patients. Direct sequencing of SOCS3 detected a TTC to TTA base change leading to the above described amino acid substitution, in three out of 127 MPD patients (2·4%) compared to two out of 160 healthy controls (1·3%) ( Fig 1B) . While this is preliminary, it represented an incidence double the normal population, but clearly a larger patient cohort should be explored.
Given that SOCS3 F136L was identified in a PV patient, as a first step we determined whether the mutant could regulate EPO responses. EPOR and JAK2 were co-expressed in combination with either SOCS3 or SOCS3 F136L in 293T cells ( Fig 1C) . As expected, SOCS3 markedly reduced JAK2 phosphorylation and was degraded concomitally ( To determine if this loss of ability to regulate signalling could also translate into deregulated cell growth, Ba/F3 cells were created that stably expressed EPOR and either a control plasmid, SOCS3 or SOCS3 F136L (Fig 1D) . Cells were grown in the presence of either 0·5 μ/ml or 5 μ/ml of EPO and the effect of SOCS3 F136L on cell proliferation was analysed using the Trypan Blue exclusion assay. At both concentrations, EPO induced strong cell growth, which at 48 h was effectively inhibited in cells expressing SOCS3 compared to cells expressing a control plasmid ( Fig 1D white versus grey bars) . On the other hand, SOCS3 F136L expressing cells showed significantly (P < 0·001) more cell growth after 48 h compared to wild-type SOCS3 expressing cells as determined by Student t Test analysis ( Fig 1D grey versus black bars) , strongly suggesting a loss of function in the SOCS3 F136L mutant.
SOCS3 F136L has an extended half-life
Phenylalanine 136 of SOCS3 is situated in a proposed PEST motif (Babon et al, 2005) within the SH2 domain. PEST sequences have been implicated in the proteasomal degradation and stability of proteins (Rechsteiner & Rogers, 1996) . We therefore hypothesised that the F136L mutation would lead to increased SOCS3 protein stability. To test this hypothesis we compared the half-life of wild-type SOCS3 and SOCS3 F136L in 293T cells (Fig 2) . Cycloheximide treated cells were stimulated with EPO for 20 min and lysates taken at 0, 2, 4 and 6 h. As expected, SOCS3 protein was rapidly degraded concomitally with the loss of phospho-JAK2. Detectable SOCS3 protein levels were decreased to background levels after 4 h with cycloheximide (Fig 2 bottom panel, lanes 1-4) . In contrast, SOCS3 F136L expression was detected for up to 6 h (Fig 2 bottom panel, lanes 5-8) . This was also reflected in the observed JAK2 phosphorylation levels, which were prolonged up to 6 h compared to wild-type SOCS3-expressing cells (Fig 2 top panel, lane 4 versus lane 8) .
The JAK2 N542-E543del mutant is constitutively active, cannot be regulated by SOCS3 and increases SOCS protein stability
To demonstrate constitutive activation of the JAK2 N542-E543del mutant, EPOR was expressed with JAK2 or JAK2 N542-E543del and the cells were incubated in serum-free medium overnight. In contrast to wild-type JAK2, the JAK2 N542-E543del mutant was strongly tyrosine phosphorylated even in the absence of cytokine stimulation ( Fig 3A lane 1 versus lane 2). As previously reported for JAK2 V617F , JAK2 N542-E543del phosphorylation was only minimally affected by SOCS3 in sharp contrast to wild-type JAK2 ( Fig 3B left panel and  right panel) . In addition, SOCS3 half-life was substantially increased in the presence of the JAK2 mutant. In the presence of SOCS3 F136L , JAK2 N542-E543del phosphorylation was also unaltered but mutant SOCS3 protein stability appeared to be further increased when compared to wild-type SOCS3 (Fig 3C) .
JAK2 N542-E543del causes accumulation of phosphorylated wild-type SOCS3 but not SOCS3 F136L
As we have previously shown that not only JAK2 V617F but also exon 12 mutants stabilise and tyrosine phosphorylate wild-type SOCS3 (Hookham et al, 2007; Elliott et al, 2009 ), the phosphorylation levels of SOCS3 F136L were examined in the presence of JAK2 N542-E543del . First EPOR, JAK2, JAK2 N542-E543del or JAK2 V617F were co-expressed with SOCS3 ( Fig  4A) . As expected, after EPO stimulation we observed marked SOCS3 tyrosine phosphorylation in the presence of both JAK2 V617F and JAK2 N542-E543del but not wild-type JAK2 (Fig 4A, top panel, lanes 4, 6 and 8 ).
To determine if SOCS3 F136L function could also be inhibited by aberrant tyrosine phosphorylation, we expressed this mutant SOCS3 F136L in the presence of JAK2 or JAK2 N542-E543del ( Fig 4B) . Additionally cells were transfected with a phosphorylation impaired SOCS3 mutant (SOCS3 YY/FF ) as negative control. Whilst no tyrosine phosphorylation was detected with any of the SOCS3 constructs in the presence of wild-type JAK2, wild-type SOCS3 was again phosphorylated when co-expressed with JAK2 N542-E543del (Fig 4B, top panel, lanes 6-8 and 10 ). Interestingly, tyrosine phosphorylation of endogenous SOCS3 was observed when JAK2 N542-E543del was expressed ( Fig 4B, top panel, lane 9) . Levels of SOCS3 F136L tyrosine phosphorylation were markedly lower than wild-type SOCS3 (Fig 4B, top panel, lane 11) .
JAK2 N542-E543del -induced cell proliferation cannot be regulated by SOCS3 or SOCS3 F136L
As neither SOCS3 nor SOCS3 F136L could efficiently regulate JAK2 N542-E543del phosphorylation we wished to determine whether either protein could regulate proliferation in cells bearing the JAK2 mutant. Ba/F3 cells stably expressing EPOR, JAK2 N542-E543del and JAK2 V617F in the presence or absence of SOCS3 or SOCS3 F136L , were grown in the presence and absence of EPO and cell proliferation was analysed as before. Figure 5A shows that SOCS3 was not only unable to regulate proliferation in the presence of JAK2 N542-E543del or JAK2 V617F , in the absence or presence of EPO stimulation, but on the contrary, SOCS3 significantly enhanced proliferation in these cells (*P < 0·05; **P < 0·001; Fig 5A) . Ba/F3 cells expressing SOCS3 F136L revealed that, similar to wild-type SOCS3, this SOCS3 mutant could not regulate JAK2 N542-E543del -induced cell proliferation but seemed to potentiate cell growth in this situation (Fig 5B) .
Discussion
This report describes that the SOCS3 F136L mutant has increased protein half-life and cannot effectively regulate EPO-induced JAK2 phosphorylation or proliferation. Interestingly, in the context of the exon 12 mutation JAK2 N542-E543del , this SOCS3 mutant was only minimally phosphorylated while tyrosine phosphorylation of wild-type SOCS3 was clearly evident. This suggests that function of the SOCS3 mutant is impaired via a different mechanism compared to wild-type SOCS3.
The SOCS3 F136L mutation is situated in the SH2 domain of SOCS3 within a region identified as a PEST motif (Babon et al, 2005) . Deletion or mutation of this motif interferes with proteasomal degradation, leading to increased protein stability (Kornitzer et al, 1994; Babon et al, 2006) . In agreement with this, the present study found SOCS3 F136L to be more stable, probably due to a disruption of the PEST motif function by the substitution of phenylalanine for leucine (Babon et al, 2005) . A follow up report by the same group though showed that deletion of this motif does not seem to interfere with SOCS3 regulatory function (Babon et al, 2006) . In contrast, our results showed that SOCS3 F136L , although still able to bind to JAK2, has impaired ability to regulate JAK2 phosphorylation and cytokineinduced cell proliferation. Under normal circumstances SOCS proteins are degraded via the proteasome alongside their target proteins (Cohney et al, 1999; Orr et al, 2007a,b) .
Furthermore it has been suggested that proteasomal degradation of proteins is catalysed by unstructured sequences (Prakash et al, 2004) . This would suggest that the SOCS3 F136L mutant binds to JAK2 and/or the EPOR, but the unstructured PEST motif is conformationally altered such that recognition by the proteasome is lost. This would lead to both stabilisation of SOCS3 and phosphorylated JAK2.
Interestingly when expressed in a cytokine-dependent cell line, both, SOCS3 F136L and wildtype SOCS3 potentiated cell growth in the presence of the JAK2 N542-E543del . The constitutively active heterozygous JAK2 mutant activates gene expression, including wildtype SOCS3 and SOCS3 F136L transcription. In addition to increased cell proliferation due to JAK2 N542-E543del , cell growth would be further increased by the additional impaired regulation of wild-type JAK2 through SOCS3 F136L .
As phosphorylation of SOCS proteins has been shown to play a role in the regulation of both their activity and stability, we examined the phosphorylation levels of wild-type and mutant SOCS3 in order to further investigate the underlying mechanisms of their functional disruption. Phosphorylation of SOCS proteins interferes with binding to Elongin C, thereby disrupting a functional E3 ligase complex and inhibiting the degradation of target proteins (Haan et al, 2003; Limnander et al, 2004) . Our recent studies detected strong tyrosine phosphorylation and stabilisation of SOCS3 in the presence of JAK2 V617F and JAK2 exon 12 mutations (Hookham et al, 2007; Elliott et al, 2009) . Surprisingly, although SOCS3 F136L is impaired in its regulatory function and shows increased stability, we could only detect minimal phosphorylation of this protein in the presence of JAK2 N542-E543del , suggesting a more complex mechanism for this SOCS3 mutant. Two previous reports showed that a tyrosine phosphorylation-deficient mutant of SOCS3 is more stable (Cacalano et al, 2001; Haan et al, 2003) , which complies with our results. However, the exact mechanism underlying the SOCS3 F136L mutation needs to be further investigated. We also identified the SOCS3 F136L mutation in a small Japanese patient cohort. Combined with the results shown here, it implies that SOCS3 F136L could have potential clinical relevance in PV. In order to determine the significance and impact of this mutation, further studies will have to be undertaken.
Taken together, the results of this study indicate that the SOCS3 F136L mutation disrupts SOCS3 function and that this mutation could have potential clinical relevance in PV. Our results suggest that the main effect of SOCS3 F136L is exerted on wild-type JAK2 and, while the JAK2 N542-E543del mutant causes constitutive EPO signalling and leads to stabilised and inactive wild-type SOCS3, the SOCS3 F136L mutation may contribute to the disease by also dysregulating wild-type JAK2. Our findings clearly indicate that SOCS3 F136L cannot The JAK2 N542-E543deletion mutant is constitutively active, cannot be regulated by SOCS3 and increases SOCS protein stability. (A) 293Tcells transfected with EPOR ± JAK2 or JAK2 N542-E543del were treated as indicated and lysates immunopreciptated with JAK2 antibody and blotted for phosphotyrosine or JAK2 (top, second panel). Whole cell lysates (WCL) were blotted for JAK2 (third panel). (B) Cycloheximide-treated 293T cells, transfected as above + SOCS3, were treated with EPO (50 μ/ml) as indicated. JAK2 phosphorylation was followed for up to 6 h. Immunoprecipitates and WCL were blotted for phosphotyrosine (left top panel), JAK2 (left second, third panel) and SOCS3 (left fourth panel). Densitometry was performed on Western Blots from B (right panel). The data is given as relative intensity of phosphotyrosine and correlating protein band. (C) 293T cells transfected with EPOR and JAK2 N542-E543del ± SOCS3, and SOCS3 F136L were analysed as described above and as indicated. JAK2 N542-E543del -induced cell proliferation cannot be regulated by SOCS3 or SOCS3 F136L . (A) Ba/F3 cells stably transfected with EPOR, JAK2 V617F or JAK2 N542-E543del ± SOCS3 were either left untreated or stimulated with EPO (1 μ/ml) for up to 48 h. Cell proliferation was determined by Trypan Blue exclusion assay and MTT assay. (B) Ba/F3 cells stably transfected with EPOR and JAK2 N542-E543del ± SOCS and SOCS3 F136L were treated and analysed as above. 
